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Abstract
Objectives: In humans, fasting leads to elevated serum GH concentrations. Traditionally, changes in
hypothalamic GH-releasing hormone and somatostatin release are considered as the main mechan-
isms that induce this elevated GH secretion during fasting. Ghrelin is an endogenous ligand of the GH
secretagogue receptor and is synthesized in the stomach. As ghrelin administration in man stimulates
GH release, while serum ghrelin concentrations are elevated during fasting in man, this increase in
ghrelin levels might be another mechanism whereby fasting results in stimulation of GH release.
Design and subjects: In ten healthy non-obese males we performed a double-blind placebo-controlled
crossover study comparing fasting with and fasting without GH receptor blockade. GH, ghrelin, insu-
lin, glucose and free fatty acids were assessed.
Results: While ghrelin levels do not vary considerably in the fed state, fasting rapidly induced a diurnal
rhythm in ghrelin concentrations. These changes in serum ghrelin concentrations during fasting
were followed by similar, profound changes in serum GH levels. The rapid development of a diurnal
ghrelin rhythm could not be explained by changes in insulin, glucose, or free fatty acid levels. Com-
pared with fasting without pegvisomant, fasting with pegvisomant did not change the ghrelin
rhythm.
Conclusions: These data indicate that ghrelin is the main driving force behind the enhanced GH
secretion during fasting.
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Introduction
In humans, fasting enhances growth hormone (GH)
secretion and amplifies GH rhythm (1). Traditionally
hypothalamic GH-releasing hormone and somatostatin
release are considered as the mechanisms whereby
somatotroph output is regulated (2). Ghrelin is an
endogenous ligand of the GH secretagogue (GHS) recep-
tor (GHS-R) and was recently isolated from rat and
human stomach, where it is synthesized in a distinct
endocrine cell type (3, 4). The gene for ghrelin encodes
a 117 amino acid prepro-ghrelin and is expressed not
only in the stomach but also in the hypothalamic
arcuate nucleus (4). Ghrelin exists in at least two
forms, an octanoylated and a non-octanoylated form.
At present only octanoylated ghrelin is thought to be
biologically active (5–7). I.v. ghrelin administration
stimulates GH secretion through the centrally located
GHS-R (8–10). Besides this effect on GH secretion a
metabolic action of ghrelin is also recognized. In
animal studies peripheral ghrelin administration also
stimulates food intake, gastric secretion, gastric motility
and adiposity (11 –13). As ghrelin administration in
man strongly stimulates GH release and, at least in
animal studies, ghrelin concentrations are elevated
during fasting, an increase in ghrelin concentration is
another potential mechanism whereby fasting can
stimulate GH release (8, 10, 12, 14).
The GHS-R was characterized using a radiolabelled
synthetic GHS called MK-0677, and subsequently it
was shown that the binding of MK-0677 to the
GHS-R could be competitively inhibited by GH-releasing
peptide-6 (GHRP-6) (15). Also, the signal transduction
pathways for MK-0677 and GHRP-6 both involve
phospholipase C, resulting in a rise in inositol triphos-
phate and intracellular calcium (15). After identifi-
cation of the GHS-R, a cell line expressing the GHS-R
was established and used to identify tissue extracts
that could stimulate the GHS-R as monitored by
increases in intracellular Ca2+ (7). By adding different
tissue extracts to such a cell line and monitoring intra-
cellular Ca2+ changes, Kojima et al. (4) isolated ghrelin
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from rat and human stomach. Taken together we can
conclude from these data that GHRP-6 and ghrelin
bind to the same receptor.
Pegvisomant is a mutated GH molecule that prevents
functional dimerization and subsequent activation of
the GH receptor (16, 17). In normal subjects and
patients with acromegaly pegvisomant effectively blocks
GH action and induces a decrease in (free) insulin-
like growth factor-I (IGF-I) concentrations (18, 19).
In the present study we have investigated the possible
role of ghrelin in the mechanism whereby fasting leads
to somatotroph hyperactivity. First, we investigated the
effects of fasting on GH and ghrelin concentrations.
Secondly, in order to investigate the possible role of
some well-known metabolic substrates in the gener-
ation of the hypothesized diurnal ghrelin rhythm, we
also assessed insulin, glucose and free fatty acid con-
centrations in serum. Thirdly, to determine the role of
GH and its effects via the GH receptor in the regulation
of ghrelin secretion during fasting, we investigated if
pretreatment with the GH receptor antagonist pegviso-
mant influenced the effect of fasting on GH and ghrelin
levels. Finally, to determine whether an auto-feedback
system for ghrelin is operative, and if so to investigate
the influence of fasting thereon, we investigated the
effect of an i.v. bolus of GHRP-6 (which does not
cross-react with the ghrelin assay) on ghrelin levels.
Subjects and methods
Ten healthy male subjects (mean (S.D.) age, 23:4^2:7
years; range 20–28) with a normal body weight
(mean (S.D.) body mass index, 21:8^1:8 kg=m2; range
19.7–25.8) were asked to participate. None of the sub-
jects had a relevant medical history or used medication.
The local ethical committee approved the study and all
subjects gave written informed consent.
We performed a double-blind placebo-controlled
crossover study comparing fasting with and fasting
without GH receptor blockade. After an overnight
fast, subjects were admitted to the Clinical Research
Unit on day 1 at 0730 h. On day 1 and day 4, a
GHRP-6 test was performed. At 1800 h on day 1
either pegvisomant 80 mg, as a single s.c. injection,
or placebo was administered. A dose of 80 mg was
chosen as this dose is capable of reducing the GH con-
centration-dependent serum IGF-I levels significantly
(18), even in acromegalic patients. From 1200 h on
day 1 until the end of the study, on day 4 at 2000 h,
subjects fasted. Blood was drawn daily at 0800, 1600
and 2400 h. Ghrelin, GH and free IGF-I levels were
determined from all samples. Between the study periods
there was a wash-out period of 3–7 weeks. GHRP-6
was administered i.v. as a bolus injection of 1mg/kg.
Blood samples were drawn 15 min and immediately
before, and 15, 30, 45, 60, 75, 90, 105 and 120 min
after GHRP-6 injection. GH levels were determined in
all samples. Ghrelin levels were determined from the
samples drawn immediately before and 15, 30, 60
and 90 min after GHRP-6 injection. Identical looking
vials with GH receptor-antagonist (pegvisomant (Soma-
vert) or placebo were supplied by Sensus Drug Develop-
ment Corporation, Austin, TX, USA.
GH samples were measured in a two-site immuno-
assay that does not cross-react with pegvisomant
(18). The assay exhibits a lower detection limit of
0.02mg/l GH, an upper end of the working range of
50mg/l for 25ml serum samples, and no cross-reaction
with pegvisomant up to a concentration of
50 000mg/l.
It should be noted that the GH values obtained with
this method are approximately 50% of those obtained
by conventional RIA methods. The inter-assay coeffi-
cient of variation (CV) values were 4.1% at 4.0mg/l
and 3.8% at 20mg/l. The intra-assay CV values were
3.4% at 0.25mg/l, 1.9% at 2.5mg/l and 4.5% at
25mg/l. Serum free IGF-I was determined with a com-
mercially available IRMA assay (Diagnostic System
Laboratories, Webster, TX, USA; intra- and inter-assay
CV values 10.3 and 10.7% respectively). Ghrelin was
detected with a commercial RIA (Phoenix Pharmaceu-
ticals, Belmont, CA, USA; intra- and interassay CV
values 4.5–5.3% and 9.0 –13.6% respectively) that
uses 125I-labelled bioactive ghrelin as a tracer molecule
and a polyclonal antibody raised in rabbits against full-
length octanoylated human ghrelin. This assay has no
cross-reactivity with other relevant molecules. Insulin
was assessed with an RIA (Medgenix Diagnostics,
Brussels, Belgium; intra- and inter-assay CV values
13.7 and 8.0% respectively). Glucose was assessed
with an automatic hexokinase method (Roche,
Almere, The Netherlands). Free fatty acids were deter-
mined with an enzymatic colorimetric method (Wako
Chemicals GmbH, Neuss, Germany; intra- and inter-
assay CV values 1.1 and 4.1% respectively).
Means were compared with the Wilcoxon signed-
ranks test. All P-values are two-sided, P-values ,0.05
were considered significant. Area under the curve
was calculated using the trapezoidal rule.
Results
Fasting rapidly induced a diurnal ghrelin and GH
rhythm (Fig. 1A) that was not seen in the fed state
(data not shown). We also assessed insulin, glucose
and free fatty acid concentrations in serum. Figure 1B
shows that that the gradual changes in serum insulin,
glucose and free fatty acid levels are not related in time
to the acute changes in systemic ghrelin and GH levels
during fasting.
Compared with fasting without pegvisomant, fasting
with pegvisomant did not change the ghrelin rhythm
(Fig. 2A). However, compared with fasting without
the presence of pegvisomant, fasting in combination
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with pegvisomant resulted in higher GH concentrations
on day 3 (from 0800 h on day 3 to 0800 h on day 4;
P , 0:05 for difference in area under the curve) (Fig.
2B). In the fasting state, both in the absence and in
the presence of pegvisomant, serum free IGF-I levels
decreased significantly. However, no additional effect
of the presence of a GH receptor antagonist was
observed (Fig. 2C).
In all subjects and under all conditions, GHRP-6
administration resulted in a powerful GH release (Fig.
3A). GHRP-6 administration had no acute modifying
effects on ghrelin levels (Fig. 3B). However, on study
day 4, the third day of fasting, early morning
GHRP-6 administration attenuated peak ghrelin levels
in the afternoon (Fig. 1A).
Discussion
In the present study we show that fasting rapidly
induces an acute and distinct diurnal rhythm in
systemic ghrelin concentrations that is not present in
the fed state. These changes in serum ghrelin levels
during fasting are followed by similar changes in
serum GH concentrations, indicating that ghrelin is
the driving force of increased GH secretion during fast-
ing. As ghrelin is mainly produced in a distinct endo-
crine cell of the stomach this implies that the
stomach can exert a direct control over the anterior
pituitary (3).
In order to investigate the possible role of some well-
known metabolic substrates in the generation of this
diurnal ghrelin rhythm, we also assessed insulin, glu-
cose and free fatty acid concentrations in serum.
Figure 1B clearly shows that that the gradual changes
in these metabolic substrates is not related in time to
the acute changes in systemic ghrelin and GH levels
during fasting. Therefore, the rapid appearance of the
observed ghrelin rhythm cannot be explained by
acute alterations in insulin, glucose or free fatty acid
levels. Interestingly, during fasting pancreatic polypep-
tide shows a similar diurnal rhythm as ghrelin does
Figure 1 Ghrelin, GH, insulin, glucose and free fatty acid concen-
trations during fasting and after a bolus injection of GHRP-6. (A)
Solid line, ghrelin levels; dotted line, GH levels. (B) Solid line,
insulin levels; small dots, glucose levels; large dots, free fatty acid
levels. Symbols represent means^S.E.M.
Figure 2 Ghrelin, GH and free IGF-I concentrations during fasting
and during fasting in the presence of the GH receptor antagonist
pegvisomant. Symbols represent means^S.E.M. Solid line, fasting;
dotted line, fasting in the presence of pegvisomant.
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(20). This opens the possibility that pancreatic polypep-
tide is responsible for the appearance of a ghrelin
rhythm. Since basal pancreatic polypeptide levels are
low in human obesity this could also explain why
circulating ghrelin levels are decreased in human obes-
ity (21, 22).
It has recently been reported by Cummings et al. (23)
that there is a large preprandial rise and postprandial
fall in plasma ghrelin levels in humans, indicating
that ghrelin might be a physiological meal initiatior.
We did not observe such a pattern in plasma ghrelin
concentrations. However, in the study by Cummings
et al. subjects were placed for 2 weeks on an outpatient
diet and total ingested calories were adjusted to main-
tain weight stability, whereas in our study subjects
received standard meals three times a day only during
admission to the Clinical Research Unit and without
adjustments to maintain a stable body weight.
Compared with fasting without pegvisomant, pre-
treatment with pegvisomant resulted in a higher GH
output on day 3 (from 0800 h on day 3 to 0800 h on
day 4). Apparently, the blockade of the GH receptor
induced higher GH levels. Serum free IGF-I levels
decreased significantly in the fasting state; this decline
was, however, not influenced by the presence or
absence of pegvisomant. Thus, disabling the GH–GH
receptor signalling system leads to an increase in GH
output, while in this same period free IGF-I levels do
not change. These data indicate that other factors
than free IGF-I, which is considered the most important
GH-dependent feedback factor on GH release (24, 25),
are responsible for the additional increase in serum
GH levels during fasting in the presence of peg-
visomant. These data can be taken to indicate an
ultra-short feedback loop of GH on its own secretion.
Moreover, from these same data we can also conclude
that GH does not exert feedback on the production of
ghrelin.
An i.v. bolus injection of GHRP-6 had no acute, i.e.
within 90 min, effect on ghrelin levels. Notably, on
study day 4, the third day of fasting, early morning
GHRP-6 administration attenuated peak ghrelin levels
in the afternoon. Therefore, we postulate that ghrelin
is, at least partially, regulated by a long-loop negative
auto-feedback system. However, because we did not
include an untreated fasted control group we cannot
be entirely sure that the observed attenuation of peak
ghrelin levels in the afternoon on the third day of fast-
ing is due to GHRP-6.
In conclusion, we have shown that fasting leads to a
diurnal ghrelin rhythm that cannot be explained by
changes in insulin, glucose or free fatty acid levels.
These changes in serum ghrelin levels during fasting
are followed by similar changes in serum GH concen-
trations, indicating that ghrelin is the driving force of
increased GH secretion during fasting. By using the
GH receptor antagonist pegvisomant we also provide
indirect evidence that these changes in serum ghrelin
levels are not regulated by the GH receptor. Finally,
we found that the administration of the synthetic
GHS, GHRP-6, was followed by a decrease of peak ghre-
lin levels, but this effect could only be observed after
several hours, suggesting that ghrelin concentrations
are, at least partially, regulated by a long-loop negative
auto-feedback control.
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